Status:
RECRUITING
Immunoglobulin G Therapy Dose Optimization
Lead Sponsor:
Rutgers, The State University of New Jersey
Conditions:
Obesity
Immune Deficiency
Eligibility:
All Genders
18-75 years
Brief Summary
The overall goal of this proposal is to investigate effects of obesity on pharmacokinetics of immunoglobulin G (IgG) and to develop strategies for optimization of dosing of IgG in obese patients. Ther...
Detailed Description
The estimated prevalence of overweight and obese individuals \>20 years in the US is 154.7 million (nearly double since the early 1960s), and over 1.6 billion people are considered overweight or obese...
Eligibility Criteria
Inclusion
- aged 18 to 75 years
- currently treated with IVIG
Exclusion
- liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal)
- reduced renal function (CrCl \< 50 mL/min)
- Patients with a pacemaker or an automatic implantable cardioverter-defibrillator
Key Trial Info
Start Date :
April 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04818177
Start Date
April 2 2021
End Date
December 1 2025
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey, United States, 08876